SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing significant volatility driven by a combination of geopolitical tensions, including concerns over Middle Eastern supply chains, and legal headwinds stemming from a jury verdict regarding past investor disclosures. Market participants are actively debating the company's long-term outlook, with discussion focused on the potential impact of high-cost 'Terafab' infrastructure plans on future profitability versus the long-term potential of its AI and robotics initiatives.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crow with knife community is rallying around the project's multichain expansion and deflationary burn mechanism, viewing the recent website update as a sign of continued development. Enthusiasts are actively comparing the token to established meme coins while promoting its organic, community-driven growth across various blockchain networks.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna is surging as a primary beneficiary of the ongoing Middle East energy crisis, with the community closely tracking the potential for a massive short squeeze driven by extremely low float and record-breaking volume. Investors are hyper-focused on the company's natural gas assets in Italy as a critical energy security play, while the message boards are buzzing with intense debate over potential warrant exercises and whether the stock's momentum can mirror past sector runners.

Guardian Metal Resources Plc engages in mining activities in the jurisdiction of Nevada. It focuses on making strategic metal discoveries across its broad project portfolio. Its projects include Pilot Mountain, Tempiute, Golconda, Garfield, Kibby Basin, and Stonewall. The company was founded on April 22, 2021 and is headquartered in London, the United Kingdom.

Guardian Metal Resources Plc - ADR

Guardian Metal Resources

Guardian Metal Resources is attracting intense community interest as it transitions to regular-way trading on the NYSE American, with investors speculating on potential momentum and liquidity swings associated with its low-float IPO status. Market participants are actively monitoring brokerage data and share availability while weighing the company's prospects within the broader metals mining sector.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick Mining is actively trending as investors react to its record-breaking Q4 earnings, which featured significant revenue growth, a substantial dividend hike, and plans for a North American asset IPO. The community is focused on Barrick's robust cash flow and its strategic move to unlock value via the NewCo spinoff, despite ongoing discussions regarding production headwinds and the broader gold mining sector's volatility.

Caledonia Mining Corp. Plc engages in the exploration, development, and production of gold and other precious metals from its mineral properties. Its projects include Blanket Gold Mine and Maligreen. The company was founded on February 5, 1992 and is headquartered in St. Helier, the United Kingdom.

Caledonia Mining Corporation Plc

Caledonia Mining is capturing investor interest as the market weighs strong profit margins and gold production growth against concerns surrounding operational risks in Zimbabwe and recent equity financing moves. The community remains divided, with long-term bulls highlighting the company's valuation gap relative to gold price appreciation and its transformative expansion projects, while others express caution over volatility and management's capital allocation strategies.

Tidal Trust II - YieldMax Gold Miners Option Income Strategy ETF

YieldMax Gold Miners Option Income Strategy ETF

GDXY is facing intense community discussion as investors weigh the impact of heavy NAV erosion against high-yield distributions in a volatile gold market. While some shareholders are aggressively buying the dip on the belief that central bank gold accumulation and macroeconomic instability will drive long-term upside, others are expressing frustration over performance and questioning the sustainability of its dividend strategy.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is facing intense volatility amid heavy short interest and speculation following a massive 50 million dollar insider stock purchase by its board chair, which has sparked a debate between retail traders expecting a short squeeze and those concerned about the company's long-term profitability. Investors are closely watching upcoming antitrust litigation developments and potential insider lock-up dynamics, while the community remains divided over whether current price levels represent a deep-value opportunity or a further decline toward single digits.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is facing significant downward pressure as investors dump long-term bonds in response to soaring energy prices and mounting concerns that the ongoing geopolitical conflict in the Middle East will fuel persistent inflation. The community is actively debating whether current Treasury yields represent a strategic entry point for a flight-to-safety trade or if the broader fiscal instability and energy shocks will continue to drag down the asset class.

Synopsys, Inc. engages in the provision of electronic design automation (EDA) software that engineers use to design and test integrated circuits (ICs). It also offers semiconductor intellectual property (IP) products. It operates through the Design Automation and Design IP segments. The Design Automation segment includes silicon design, verification of products and services, and Ansys products, and system integration of products and services. The Design IP segment refers to interface, foundation, security, and embedded processor IP, IP subsystems, and IP implementation services that serve companies primarily in the semiconductor and electronics industries. The company was founded by Aart J. de Geus, Bill Krieger, Dave Gregory, and Rick Rudell in December 1986 and is headquartered in Sunnyvale, CA.

Synopsys, Inc.

Synopsys Inc

Synopsys is trending following news that Elliott Investment Management has built a multibillion-dollar stake in the company, with investors discussing the potential for the activist fund to push for better monetization and improved margins. The community is actively debating the company's valuation relative to the broader semiconductor sector and whether it can effectively leverage its AI-driven design tools to maintain its market position.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dagco Inc. Purchases Shares of 577,540 SELLAS Life Sciences Group, Inc. $SLS

Dagco Inc. purchased a new stake in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 577,540 shares of the company's stock, va...

Penny Stocks To Research - March 22nd

Kosmos Energy, Co-Diagnostics, SELLAS Life Sciences Group, JetBlue Airways, BigBear.ai, Banco Bradesco, and Bitfarms are the seven Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are shares of very small companies that trade at low pricestypically under $5...

Penny Stocks To Watch Now - March 21st

Kosmos Energy, Co-Diagnostics, SELLAS Life Sciences Group, JetBlue Airways, and BigBear.ai are the five Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are...

<ul class="summary-bullets"><li>Both SLS009 and Galinpepimut-S are designed to address different stages of acute myeloid leukemia.</li><li>Alliance Global said the updates on SLS009 and GPS strengthen the investment thesis for the company’s pipeline.</li><li>SLS009 is being tested in early-stage acute myeloid leukemia, showing promising effectiveness and tolerability in patients.</li></ul>Alliance Global has increased its price target for Sellas Life Sciences (SLS) shares to $10 from $7.50, maintaining a ‘Buy’ rating after the biotech firm shared progress updates on its clinical-stage treatments.The new price target implies a potential 92% upside to the stock’s closing price on Thursday. The firm’s optimism comes as Sellas Life Sciences detailed developments for its two leading candidates, SLS009 and Galinpepimut-S.<h2 class="st-heading-2">Clinical Advancements Highlight Potential</h2>Both SLS009 and Galinpepimut-S are designed to address different stages of acute myeloid leukemia (AML) in patients. Alliance Global said that these updates strengthen the investment thesis for the company’s pipeline, offering potential upside for shareholders, according to TheFly.&nbsp;LS009 is currently in clinical testing for patients in the initial phases of acute myeloid leukemia, with the company reporting encouraging signs of efficacy and tolerability. The therapy is being closely watched as a potential new treatment avenue for patients with limited options.On Tuesday, Sellas announced that preclinical data for its CDK9 inhibitor, SLS009 (tambiciclib), will be presented in a poster session at the American Association for Cancer Research (AACR) conference, April 17–22 in San Diego.<a href="https://stocktwits.com/symbol/SLS">Sellas Life Sciences' stock</a> traded over 5% higher on Friday morning. Retail sentiment on Stockwtits around the stock remained in ‘bearish’ territory amid ‘low’ message volume levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_20_104016_png_a1cf576a4e.webp" alt="SLS’s Sentiment Meter and Message Volume as of 10:15 a.m. ET on Mar. 20, 2026 | Source: Stocktwits" width="931" height="98"><figcaption>SLS’s Sentiment Meter and Message Volume as of 10:15 a.m. ET on Mar. 20, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Galinpepimut-S Focuses On Advanced Patients</h2>Galinpepimut-S is aimed at individuals with more progressed disease. Early trial results suggest it could complement existing therapies, providing a targeted immunotherapy approach.&nbsp;<blockquote>“We are advancing toward the final analysis of our Phase 3 REGAL trial evaluating GPS in AML patients who have achieved complete remission following second-line salvage therapy.”— Angelos Stergiou, President And CEO, Sellas Life Sciences</blockquote>The trial will conduct its final analysis after 80 survival events; as of Dec. 26, 2025, 72 events occurred, with the study still blinded, pending database lock, analysis, and topline results release.SLS stock has gained over 43% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/smcx-etf-plummets-55-as-super-micro-legal-troubles-and-export-violations-weigh-on-investor-sentiment/cZ3XAV4RILj">SMCX ETF Plummets 55% As Super Micro Legal Troubles And Export Violations Weigh On Investor Sentiment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena.

SLS Stock In Focus As Alliance Global Sees 92% Upside Following AML Trial Updates

The company will present preclinical data on SLS009 in a poster session at the American Association for Cancer Research.

Equity

The company will present preclinical data on SLS009 in a poster session at the American Association for Cancer Research.


SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up on Earnings Beat

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up Following Better-Than-Expected Earnings...

<ul class="summary-bullets"><li>Net loss in FY25 narrowed to $26.9 million from $30.9 million a year ago, with R&amp;D costs falling to $16 million.</li><li>Phase 3 Regal AML trial nears final analysis, with 72 of 80 required survival events reached, keeping focus on upcoming topline data.</li><li>SLS009 advances into first-line AML trials, backed by prior 46% response rate data and supported by upcoming AACR preclinical results.</li></ul>Shares of Sellas Life Sciences Group Inc. (SLS) posted modest gains in extended trading on Thursday after the company reported a narrower full-year loss and a stronger cash position, as investors turned their focus to a closely watched Phase 3 AML trial nearing its final trigger.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> snapped three straight sessions of losses on Thursday to end 5% higher at $5.20,&nbsp;and gained 0.4% in the extended session. However, shares are headed for their worst week in over a month.<h2 class="st-heading-2">SLS FY25 Review</h2>The biotech firm reported a net loss of $26.9 million, or $0.25 per share, for the year ended Dec. 31, 2025, compared with a net loss of $30.9 million, or $0.5 per share, in 2024. Research and development expenses declined to $16 million from $19.1 million, while general and administrative expenses were largely unchanged at $12.3 million.The decline in expenses was primarily driven by lower clinical trial and regulatory consulting costs following the completion of enrollment in the Phase 3 Regal study in early 2024. Sellas also reported receiving $67.2 million in gross proceeds from warrant exercises during 2025.Sellas ended 2025 with $71.8 million in cash and cash equivalents and said it received an additional $42.6 million in proceeds from warrant exercises in the first quarter of 2026.&nbsp;“With a catalyst rich outlook, continued clinical execution, our strongest financial position in history, and expansion into earlier treatment settings, we look forward to an important year ahead,” CEO Angelos Stergiou said in a statement.Sellas said 2026 is shaping up to be a “pivotal year,” citing progress across its acute myeloid leukemia (AML) programs and upcoming catalysts.<h2 class="st-heading-2">GPS Trial Moves Closer To Final Analysis</h2>Investor attention remains centered on Sellas’ Phase 3 Regal trial evaluating galinpepimut-S (GPS) in AML patients who have achieved remission following second-line salvage therapy.The event-driven trial is designed to trigger&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-falls-premarket-investors-cautious-as-aml-trial-readout-nears/cZdVgoyRIId">final analysis</a> upon reaching 80 survival events. The company said 72 events had been recorded as of Dec. 26, with the study remaining fully blinded. Once the required event threshold is reached, Sellas will proceed with database lock, statistical analysis, unblinding and disclosure of topline results.<h2 class="st-heading-2">Sellas Builds Momentum With SLS009 Pipeline</h2>The company also highlighted its second pipeline candidate, SLS009, which is being advanced into earlier lines of treatment, with the first patient already dosed in an 80-patient Phase 2 trial in newly diagnosed AML.In January, Sellas entered a collaboration with Impact-AML to advance the program in Europe, with a study expected to enroll around 40 patients starting in the second quarter.The program builds on previously reported Phase 2 data, where SLS009, used alongside azacitidine and venetoclax, two commonly used AML therapies, achieved a 46% response rate in relapsed or hard-to-treat AML, including 29% complete responses, with improved survival and no dose-limiting toxicities observed.<h2 class="st-heading-2">Sellas Flags ‘Compelling’ Early Data For SLS009</h2>The company also pointed to preclinical findings supporting SLS009, with data to be presented at the American Association for Cancer Research (AACR)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-potent-aml-drug-data-aacr-cancer-summit-momentum/cZ37TBERIg5">next month</a>, showing the drug induces cancer cell death in AML models, including those with high-risk ASXL1 and TP53 mutations, with early changes seen in key survival proteins such as MCL-1 and survivin.The presentation comes ahead of earlier preclinical results shared at the European Society for Medical Oncology Congress, where SLS009 showed a statistically significant survival benefit in a T-cell leukemia model, both as a standalone therapy and in combination with venetoclax.Stergiou called the findings “compelling new data,” adding that SLS009 showed activity in AML models with high resistance.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for SLS was ‘bearish’ amid ‘low’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_089ae693bf.webp" alt="sls ss.png" width="967" height="141"><figcaption>SLS sentiment and message volume as of March 19 | Source: Stocktwits</figcaption></figure>One user said the stock’s direction largely depends on the upcoming GPS data, with strong results potentially driving sharp gains and weaker outcomes posing downside risk.<stembedurl>https://stocktwits.com/Andi77/message/648041521</stembedurl>Another user said, “THE DATA JUST NEED TO BE “GOOD ENOUGH” (HR 0.636) TO GET FDA APPROVAL. SO IT IS EITHER $70 OR $180.”<stembedurl>https://stocktwits.com/Duncan74/message/648045039</stembedurl>SLS stock has rocketed over 300% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

SLS stock has rocketed over 300% over the past year. (Photo credit: Getty Images)

SLS Stock Pops After-Hours As Loss Shrinks, Cash Swells — All Eyes On High Stakes AML Trial In 'Pivotal' 2026

The company’s cash stood at $71.8 million at the end of the year, marking the company’s strongest balance sheet so far.

SELLAS Life Sciences Group (NASDAQ:SLS) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) posted its earnings results on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01...

<ul class="summary-bullets"><li>The company flagged “potent” preclinical data for its AML drug SLS009 ahead of the AACR 2026 conference.</li><li>CEO Angelos Stergiou called the findings “compelling,” highlighting activity even in high-risk AML mutations like ASXL1 and TP53.</li><li>Sellas recently enrolled its first patient in a Phase 2 AML trial, targeting hard-to-treat groups.</li></ul>Shares of Sellas Life Sciences Group, Inc. (SLS) jumped nearly 6% in overnight trading on Wednesday after the company flagged “potent” new preclinical data for its acute myeloid leukemia (AML) drug SLS009, with the findings set to be unveiled at a cancer conference next month.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> recorded its second straight session of losses on Tuesday, declining nearly 6% to $5.04.<h2 class="st-heading-2">CEO Flags ‘Compelling’ SLS009 Findings</h2>The company said it will present the data at the American Association for Cancer Research (AACR) 2026 in San Diego, drawing investor focus to its advancing acute myeloid leukemia (AML) program.Sellas said early lab data show that SLS009 helps drive leukemia cells toward self-destruction by blocking the signals that normally keep them alive, including proteins such as MCL-1 and Survivin.The company said the drug increased caspase-3 levels, a key indicator that cancer cells are dying, while lowering MCL-1. With repeated dosing, the drug became more effective, with its potency improving significantly over time and its effects becoming stronger the longer it was used.In a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/feed/update/urn:li:activity:7439771995292057600/?originTrackingId=6fSXlWZTuGLQXVW%2B%2FbRQyg%3D%3D">LinkedIn Post</a> late Monday, CEO Angelos Stergiou said the findings represent “compelling new data,” adding that SLS009 has shown the ability to deliver potent activity even in AML models with high resistance, including those with ASXL1 and TP53 mutations.<h2 class="st-heading-2">Clinical Momentum Builds For SLS009</h2>The update comes days after Sellas announced the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-in-spotlight-first-aml-patient-enrolled-in-phase-2-leukemia-trial/cZduE6RRI9L">first patient</a> enrollment in its Phase 2 trial evaluating SLS009 in newly diagnosed AML patients. The study is expected to enroll around 80 patients across the U.S. and Europe, targeting individuals unlikely to benefit from standard therapies such as Venetoclax and Azacitidine, as well as those showing early resistance.The trial builds on prior Phase 2 results in relapsed or refractory AML, where SLS009, in combination therapy, delivered overall response rates of up to 50% in certain subgroups, with favorable safety and tolerability. Topline data from the ongoing trial is expected in the fourth quarter.<h2 class="st-heading-2">GPS Phase 3 Trial Nears Key Readout</h2>Investor attention is also focused on Sellas’ lead immunotherapy,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-falls-premarket-investors-cautious-as-aml-trial-readout-nears/cZdVgoyRIId">GPS (Galinpepimut-S)</a>, which is currently being evaluated in a late-stage Phase 3 trial.The event-driven Regal study is approaching its final analysis trigger, with 72 of 80 required survival events already recorded. The trial is designed to assess whether GPS can improve overall survival in AML patients in remission.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for SLS was ‘bearish’ amid ‘normal’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_0f6aedd38a.webp" alt="sls ss.png" width="966" height="141"><figcaption>SLS sentiment and message volume as of March 18 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/BIOTECH_GURU/message/647821612">said</a>, “Ignoring the noise and waiting for a news drop when it happens. The longer we wait the higher likelihood of overwhelmingly positive results.”&nbsp;<stembedurl>https://stocktwits.com/BIOTECH_GURU/message/647821612</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Johnmtnb2018/message/647821213">said</a>, “Crazy Action Overnight $5.80. Something Bigly Positive gps regal p3 news coming!”<stembedurl>https://stocktwits.com/Johnmtnb2018/message/647821213</stembedurl>SLS stock has surged over 300% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

SLS stock has surged over 300% over the past year. (Photo credit: Getty Images)

SLS Stock Jumps Overnight: ‘Potent’ AML Drug Data Ahead Of Cancer Summit Fuels Fresh Momentum

Shares of Sellas Life Sciences Group, Inc. (SLS) jumped nearly 6% in overnight trading on Wednesday after the company flagged “potent” new preclinical data for its acute myeloid leukemia (AML) drug SLS009

Investors are also watching the late-stage GPS immunotherapy trial, which is nearing final analysis with 72 of 80 survival events recorded.

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 5.3% - Here's Why

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 5.3% - What's Next...

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 9.3% Higher - What's Next?

SELLAS Life Sciences Group (NASDAQ:SLS) Trading Up 9.3% - Time to Buy...

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Strategic institutional positioning and new banking ties suggest a high-level corporate buyout is moving toward completion.

Investors are laser-focused on upcoming Phase 3 readout results as the primary driver for a potential valuation breakout.

Significant volume on the tape is interpreted by traders as the clearing of legacy warrants, removing technical supply pressure.

Debates rage between bulls and bears over whether aggressive ATM activity and volume shifts indicate dilution or expert maneuvering.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '27	--	-$0.13	--	N/A
Q1 '27	--	-$0.07	--	N/A
Q1 '26	-$0.06	--	--	N/A
Q4 '25	-$0.06	-$0.05	21.05%	BEAT
Q3 '25	-$0.08	-$0.06	21.74%	BEAT

SLS
SELLAS Life Sciences Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '27

Historical Earnings

Latest SLS News

SLSSELLAS Life Sciences Group Inc